These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29908877)

  • 1. Prognosis, Effect Modification, and Mediation.
    Vickers AJ; Steineck G
    Eur Urol; 2018 Sep; 74(3):243-245. PubMed ID: 29908877
    [No Abstract]   [Full Text] [Related]  

  • 2. Distinguishing Between Efficacy and Real-World Effectiveness: The Case for Thinking Beyond Classic Randomized Controlled Trial Design.
    Sites BD; Masaracchia MM; Davis M
    Reg Anesth Pain Med; 2017; 42(2):131-132. PubMed ID: 28207640
    [No Abstract]   [Full Text] [Related]  

  • 3. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?
    Seyednasrollah F; Mahmoudian M; Rautakorpi L; Hirvonen O; Laitinen T; Jyrkkiö S; Elo LL
    Eur Urol; 2017 May; 71(5):838-840. PubMed ID: 28189430
    [No Abstract]   [Full Text] [Related]  

  • 4. The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD.
    Pacyna JE; Kim S; Yost K; Sedlacek H; Petereit D; Kaur J; Rapkin B; Grubb R; Paskett E; Chang GJ; Sloan J; Basch E; Major B; Novotny P; Taylor J; Buckner J; Parsons JK; Morris M; Tilburt JC
    BMC Cancer; 2018 Aug; 18(1):788. PubMed ID: 30081846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covariate adjustment for randomized controlled trials revisited.
    Wang J
    Pharm Stat; 2020 May; 19(3):255-261. PubMed ID: 31863636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.
    Lu QS; Chow SC; Tse SK
    J Biopharm Stat; 2019; 29(2):400-410. PubMed ID: 30599798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 8. [Introduction to randomized trials: the choice of endpoint].
    Simon EG; Fouché CJ; Perrotin F
    Gynecol Obstet Fertil; 2011 Oct; 39(10):595-6. PubMed ID: 21924939
    [No Abstract]   [Full Text] [Related]  

  • 9. PR07 interim results: lymph node status -- the elephant in the room.
    Kirollos M
    Eur Urol; 2012 Sep; 62(3):568. PubMed ID: 22727997
    [No Abstract]   [Full Text] [Related]  

  • 10. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
    Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing multiregional trials under the discrete random effects model.
    Lan KK; Pinheiro J; Chen F
    J Biopharm Stat; 2014; 24(2):415-28. PubMed ID: 24605977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical assessment of biosimilarity based on the relative distance between follow-on biologics for binary endpoints.
    Shin W; Kang SH
    J Biopharm Stat; 2016; 26(2):227-39. PubMed ID: 25372220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Bayesian analyses to doubly randomized delayed start, matched control designs to demonstrate disease modification.
    Turkoz I; Sobel M; Alphs L
    Pharm Stat; 2019 Jan; 18(1):22-38. PubMed ID: 30221459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
    Potthoff RF; Halabi S
    Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Joint hypothesis testing and gatekeeping procedures for studies with multiple endpoints.
    Mascha EJ; Turan A
    Anesth Analg; 2012 Jun; 114(6):1304-17. PubMed ID: 22556210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance.
    Leapman MS; Ameli N; Cooperberg MR; Chu C; Hussein A; Shinohara K; Carroll PR
    Eur Urol; 2017 Sep; 72(3):329-332. PubMed ID: 27157998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating and adjusting for premature censoring of progression-free survival.
    Rothmann M; Koti K; Lee KY; Lu HL; Shen YL; Zhang JJ; Jin M; Zhou H
    J Biopharm Stat; 2013; 23(5):1091-105. PubMed ID: 23957518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.